Publications by authors named "Howard A Ball"

Claim this Profile
F
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer.
Filip Janku, Patricia LoRusso, Aaron S Mansfield, Rita Nanda, Alexander Spira, Howard A Ball

Invest New Drugs· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
Noboru Yamamoto, Baek-Yeol Ryoo, Bhumsuk Keam, Masatoshi Kudo, Chia-Chi Lin, Howard A Ball

Invest New Drugs· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
Al B Benson, Igor Kiss, John Bridgewater, Ferry A L M Eskens, Carolyn Sasse, Howard A Ball

Clin Cancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Tianhong Li, Patricia LoRusso, Michael L Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A Ball

J Hematol Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Elisabeth I Heath, Jeffrey Infante, Lionel D Lewis, Thehang Luu, Joe Stephenson, Howard A Ball

Cancer Chemother Pharmacol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Ruth Plummer, Ayman Madi, Melinda Jeffels, Heike Richly, Bahar Nokay, Howard A Ball

Cancer Chemother Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
Howard A Burris, Afshin Dowlati, Rebecca A Moss, Jeffrey R Infante, Suzanne F Jones, Howard A Ball

Mol Cancer Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Chun-Fang Xu, Nan X Bing, Howard A Ball, Dilip Rajagopalan, Cora N Sternberg

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders.
Howard A Ball, Michael R Van Scott, Cynthia B Robinson

Clin Rev Allergy Immunol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Bruno Morgan, Anne L Thomas, Joachim Drevs, Juergen Hennig, Martin Buchert, Howard A Ball

J Clin Oncol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma.
Howard A Ball, Anthony Sandrasagra, Lei Tang, Mike Van Scott, James Wild

Am J Pharmacogenomics· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist.
Marc Gerspacher, Christine Lewis, Howard A Ball, Colin Howes, Natarajan Subramanian

J Med Chem· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biphenyl derivatives as novel dual NK(1)/NK(2)-receptor antagonists.
Robert Mah, Marc Gerspacher, Andreas von Sprecher, Stefan Stutz, Vincenzo Tschinke, Howard A Ball

Bioorg Med Chem Lett· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and development of respirable antisense therapeutics for asthma.
Anthony Sandrasagra, Sherry A Leonard, Lei Tang, Kelly Teng, Yukui Li, Howard A Ball

Antisense Nucleic Acid Drug Dev· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis